Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT)-Reference-Cited by-同舟云学术

Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT)

Published:2010-11-19 Issue:21 Volume:116 Page:1973-1973
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gugliotta Luigi¹,Papayannidis Cristina²,Piccin Andrea³,Tieghi Alessia⁴,Vianelli Nicola⁵,Scalzulli Potito Rosario⁶,Candoni Anna⁷,Dragani Alfredo⁸,Patriarca Andrea⁸,Lunghi Monia⁹,Ciancia Rosanna¹⁰,Martinelli Vincenzo¹¹,Liberati Anna Marina¹²,Specchia Giorgina¹³,Imovilli Annalisa¹⁴,Vannucchi Alessandro M.¹⁵,Di Gaetano Rosa¹⁶,Randi Maria Luigia¹⁷,Passamonti Francesco¹⁸,Palmieri Fausto¹⁹,Mazzucconi Maria Gabriella²⁰,Mastrullo Lucia²¹,Cimino Giuseppe²²,Pierri Ivana²³,Cacciola Emma²⁴,Lucchesi Alessandro²⁵,Luraschi Annalisa²⁶,Martinelli Giovanni²,Baccarani Michele²

Affiliation:

1. S. Orsola-Malpighi Hematology-Oncology, University of Bologna, Bologna, Italy,

2. Department of Hematology-Oncology, University of Bologna, Bologna, Italy,

3. Hematology Unit, Ospedale Civile, Bolzano, Italy,

4. Hematology, Reggio Emilia, Reggio Emilia, Italy,

5. Istituto di Ematologia L. A. Seràgnoli, Policlinico Sant’Orsola Malpighi, Bologna, Italy,

6. Hematology Unit, Casa sollievo della Sofferenza, S. Giovanni Rotondo (FG), Italy,

7. Chair and Division of Haematology, University Hospital of Udine., Chair and Division of Haematology, University Hospital of Udine., Udine,

8. Hematology Unit, Ospedale S. Spirito, Pescara, Italy,

9. Division of Hematology, BRMA - Amedeo Avogadro University of Eastern Piedmont, Novara, Italy,

10. Hematology, Federico II University, Napoli, Italy,

11. Hematology Division, Department of Biochemistry and Medical Biotechnology, University Federico II, Naples, Italy,

12. Hematology Unit, Università, Terni, Italy,

13. University of Bari, Bari, Italy,

14. Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy,

15. Hematology, Dept of Medical and Surgical Care, Florence, Italy,

16. Hematology Unit, Ospedale Castelfranco Veneto, Castelfranco Veneto,

17. University of Padua, Italy,

18. Department of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy,

19. Hematology Unit, AORN S. Giuseppe Moscsti, Avellino,

20. Department of Cellular Biotechnologies and Hematology, University of Rome, Rome, Italy,

21. Hematology Unit, Ospedale S. Gennaro, Napoli,

22. Univ.Polo Pontino, Latina, Italy,

23. Chair of Hematology, University of Genova, Genova,

24. Biomedical Science, Section of Hematology, University of Catania, Catania, Italy,

25. Hematology Unit, Ospedale, L’Aquila, Italy,

26. Hematology Unit, Ospedale di Verbania, Verbania, Italy

Abstract

Abstract Abstract 1973 Background. Hematological and extra-hematological adverse events associated to Hydroxyurea (HU) treatment in patients with chronic myeloproliferative neoplasms (MPN) are object of particular interest in the Ph-negative MPN since they can significantly limit the HU use. Objective. To evaluate the extra-hematological adverse events associated to HU treayment in a large cohort of Essential Thrombocythemia (ET) patients. Material and Methods. One thousand and seventy-five out of the 2005 ET patients registered in the RIT were treated with HU and are the object of this report. The patients, 641 females (59.6%) and 434 males (40.4%), diagnosed according to the PVSG or WHO criteria in 54 hematological centers of the RIT, started treatment with HU as first (92%) or second (8%) line, at median age of 65 years.The mean duration of HU treatment was 3.3 years. The HU treatment was withdrawn in 221 (20.5%) patients after a mean of 3.0 years.The administered dose of HU was 0.25–3.0 g/day (median 1), and a mean cumulative dose was 1113 g. The extra-hematological adverse events (EHAEs) observed during the HU treatment were distinguished in HU related AEs (HU-EHAEs), ET related AEs (ET-EHAEs) and HU or ET unrelated AEs (U-EHAEs).Results. During the HU treatment (3587 pt-y) 378 EHAEs were reported in 207 (19.3%) patients, being the HU-EHAEs 244 (6.8/100 pt-y) in 170 (15.8%) patients. In detail, the HU-EHAEs were: dermatological in 108 (48.3%) cases (38 hyperpigmentation, 26 leg ulcers, 22 maculo-papular rash, 10 lichenoid eruptions, 5 skin cancer, 4 alopecia); gastro-intestinal in 80 (32.8%) cases (37 nausea/vomiting, 30 diarrhea, 13 gastro-intestinal intolerance); systemic in 35 (14.3%) cases (28 fever, 7 fatigue); neurological in 19 (7.8%) cases (headache); miscellanea in 2 (0.8%) cases. Conclusion. This preliminary analysis in 1075 ET patients of the Registro Italiano Trombocitemia (RIT) treated with HU shows that the extra-hematological adverse events referred to the HU (HU-EHAEs) occurred with not negligible rate (6.8/100 pt-y) and need to be object of attention in the management of ET patients. Disclosures: No relevant conflicts of interest to declare.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation;Global Journal of Medical and Clinical Case Reports;2023-01-25

2. Essential Thrombocythemia: The Dermatologic Point of View;Clinical Lymphoma Myeloma and Leukemia;2015-12